[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ace Cells Lab Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100607691","phase-4-assessment-of-cataclear-tear-film-stability-tear-volume-and-dry-eye-symptoms-using-stem-cells-fortified-eye-drops-100607691",false,"NCT07191847","Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops","CaraClear, Studying Lens Peptides and Extra Ocular Tissue Managed by ACE Pico Protocol in Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops","CataClear","Inclusion Criteria:\n\n* Adults aged 18-80 years.\n* Diagnosed with dry eye disease (based on clinical criteria such as OSDI scores and Schirmer test results).\n\nExclusion Criteria:\n\n* Exclusion Criteria:\n\n  * History of ocular surgery or trauma.\n  * Other ocular diseases (e.g., glaucoma, keratitis).\n  * Systemic conditions that may interfere with study outcomes (e.g., autoimmune diseases).","ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Dry Eye Disease (DED) is a multifactorial condition that affects the ocular surface, leading to discomfort, tear film instability, and potential visual disturbances. Its global prevalence ranges between 5% and 50%, making it a significant cause of reduced quality of life and a growing burden on healthcare systems. Cataract, defined as a progressive opacification of the lens, remains the leading cause of preventable blindness worldwide, responsible for about 33% of all cases, affecting an estimated 94 million people. Its incidence increases with age and is influenced by factors such as ultraviolet exposure, diabetes, smoking, and genetic predisposition. Low- and middle-income countries (LMICs) face a disproportionately high burden due to limited access to surgical care. The economic impact of cataract is profound, including both direct costs (surgery, post-op care) and indirect costs (lost productivity, caregiver dependency), with global productivity losses estimated at $53 billion annually. Beyond economics, cataract significantly impairs quality of life, contributing to psychological distress, depression, loss of independence, and increased risk of cognitive decline. Addressing this burden requires integrated strategies that ensure equitable access to treatment, reduce financial barriers, and include psychosocial support. In parallel, emerging regenerative therapies such as stem cell-fortified eye drops offer new hope. These treatments, utilizing mesenchymal stem cells (MSCs), aim to restore ocular surface health in conditions like DED by reducing inflammation and enhancing tissue repair. The current study evaluates the efficacy of such drops in improving tear film stability, tear volume, and overall clinical symptoms using advanced diagnostic tools.",[28,29],"Dry Eye","Cataract",[31,32],"dryeye","catclear","RECRUITING","2025-09-22",{"date":36,"type":37},"2025-09-25","ACTUAL",{"date":39,"type":37},"2025-04-22",{"date":41,"type":22},"2026-01-01",{"name":43,"class":44},"Ace Cells Lab Limited","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":66,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100607373","phase-4-ace-reno-pico-cell-matrix-and-its-effect-on-egfr-in-chronic-kidney-diseases-100607373","NCT07187713","ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases","ACE Reno, Effect of Pico Cell Matrix on Patients With Micro-albuminuria, Proteinuria or CKD (of Any Degree) Due to Diabetes Mellitus, Autoimmune, Miscellaneous Aetiology","ACE Reno","Inclusion Criteria:\n\n* Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi\u002FARB, SGLT2i, or MRA allowed.\n\nExclusion Criteria:\n\n* Recent kidney transplant (\\\u003C12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components.",{"count":21,"type":22},[25],"This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria\u002Fproteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux\u002FUTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-transplant proteinuria.\n\nNephropathy remains a global health burden, with \\~9-10% of the population affected by chronic kidney disease (CKD), equating to \\>750 million individuals worldwide. The socioeconomic costs are substantial: in England CKD costs \\~£7 billion annually, projected to rise to \\~£14 billion by 2033; in Malaysia, prevalence rose from 9% to 15.5% within 7 years; in Egypt, CKD imposes heavy familial and financial burdens, especially for pediatric patients; in Turkey, CKD is among the top causes of disability, linked to the rising tide of diabetes, obesity, and hypertension.\n\nACE Reno is designed to address multiple drivers of CKD progression - glomerulosclerosis, fibrosis, endothelial dysfunction, and maladaptive RAAS\u002Faldosterone signaling - through its peptide components that mimic antifibrotic (BMP-7, HGF, Klotho-like) and vasodilatory\u002FcGMP-mediated (natriuretic peptide-like) pathways.",[58,59,60,61,62,63,64,65],"Hypertensive Nephropathy","Auto Immune Disorders","Chronic Kidney Disease","Chronc Kidney Disease Stage 5","Chronic Kidney Disease (Stage 3-4)","Chronic Kidney Disease (Stages 4 and 5)","Microalbuminuria","Diabetic Nephropathies",[67,68,69],"chronic kidney disease","ckd","nephropathy","2025-09-19",{"date":72,"type":37},"2025-09-23",{"date":74,"type":22},"2025-09-20",{"date":76,"type":22},"2026-12-31",{"name":43,"class":44},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100576606","phase-1-evaluating-a-new-peptide-therapy-for-retinal-diseases-amd-diabetic-retinopathy-and-dystrophies-100576606","NCT06787482","Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies","Open Label, Interventional Single Arm Study Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies","Retino","Inclusion Criteria:\n\n* • Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP.\n\n  * Visual acuity of ≥1\u002F60 in at least one eye.\n  * Stable ocular and systemic condition over the past six months.\n  * Ability to provide written informed consent\n\nExclusion Criteria:\n\n* • Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy).\n\n  * Recent ocular surgery (within six months) or current use of investigational drugs.\n  * Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, autoimmune diseases).\n  * Pregnancy or lactation.",{"count":87,"type":22},100,[89,90],"PHASE1","PHASE2","Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy consists of peptides derived from fetal tissues, mesenchymal stem cells (MSCs), and bioactive growth factors, administered sublingually for systemic absorption.\n\nStudy Objectives:\n\nPrimary Objectives: Assess safety and tolerability, and evaluate the therapy's effects on retinal function and structure.\n\nSecondary Objectives: Explore improvements in visual acuity, retinal thickness, vascular health, and disease biomarkers.\n\nStudy Design:\n\nType: Open-label, single-arm interventional study. Duration: 12 months.\n\nParticipants: 150 adults, divided into three cohorts:\n\nRetinal dystrophies. AMD (dry and wet forms). DR (moderate NPDR and PDR).\n\nIntervention:\n\nA sublingual solution containing peptides and growth factors, taken 4 times daily.\n\nOutcome Measures:\n\nPrimary Outcomes: Safety (adverse events) and tolerability (treatment adherence).\n\nSecondary Outcomes:\n\nFunctional: Visual acuity and field sensitivity improvements. Structural: Retinal thickness and vascular health. Biomarkers: Serum VEGF, oxidative stress, and inflammatory markers.\n\nStudy Procedures:\n\nMonthly follow-ups for safety monitoring, vision tests, retinal imaging (OCT, FA), and blood biomarker analysis.\n\nComprehensive evaluations at baseline, 6 months, and 12 months. Significance: The study aims to provide an innovative, non-invasive treatment for debilitating retinal conditions, potentially improving vision and retinal health through systemic therapy.",[93,94,95],"Retinitis Pigmentosa (RP)","Age Related Macular Degeneration","Diabetic Retinopathy","2025-04-23",{"date":98,"type":37},"2025-04-25",{"date":100,"type":37},"2024-11-12",{"date":102,"type":22},"2025-12",{"name":43,"class":44},2,""]